Lipella Total Assets from 2010 to 2024
| LIPO Stock | 2.80 0.16 5.41% |
Total Assets | First Reported 2010-12-31 | Previous Quarter 3.6 M | Current Value 2.8 M | Quarterly Volatility 1.8 M |
Check Lipella Pharmaceuticals financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Lipella Pharmaceuticals' main balance sheet or income statement drivers, such as Depreciation And Amortization of 1.6 K, Interest Expense of 9.6 K or Selling General Administrative of 2.3 M, as well as many indicators such as Price To Sales Ratio of 176, Dividend Yield of 0.0 or PTB Ratio of 16.36. Lipella financial statements analysis is a perfect complement when working with Lipella Pharmaceuticals Valuation or Volatility modules.
Lipella | Total Assets |
Latest Lipella Pharmaceuticals' Total Assets Growth Pattern
Below is the plot of the Total Assets of Lipella Pharmaceuticals Common over the last few years. Total assets refers to the total amount of Lipella Pharmaceuticals assets owned. Assets are items that have some economic value and are expended over time to create a benefit for the owner. These assets are usually recorded in Lipella Pharmaceuticals books under different categories such as cash, marketable securities, accounts receivable,prepaid expenses, inventory, fixed assets, intangible assets, other assets, marketable securities, accounts receivable, prepaid expenses and others. It is the total value of all owned resources that are expected to provide future economic benefits to the business, including cash, investments, accounts receivable, inventory, property, plant, equipment, and intangible assets. Lipella Pharmaceuticals' Total Assets historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in Lipella Pharmaceuticals' overall financial position and show how it may be relating to other accounts over time.
| View | Last Reported 3.58 M | 10 Years Trend |
|
Total Assets |
| Timeline |
Lipella Total Assets Regression Statistics
| Arithmetic Mean | 1,097,298 | |
| Geometric Mean | 331,518 | |
| Coefficient Of Variation | 159.61 | |
| Mean Deviation | 1,323,478 | |
| Median | 118,917 | |
| Standard Deviation | 1,751,437 | |
| Sample Variance | 3.1T | |
| Range | 5.8M | |
| R-Value | 0.72 | |
| Mean Square Error | 1.6T | |
| R-Squared | 0.51 | |
| Significance | 0 | |
| Slope | 280,654 | |
| Total Sum of Squares | 42.9T |
Lipella Total Assets History
Other Fundumenentals of Lipella Pharmaceuticals
Lipella Pharmaceuticals Total Assets component correlations
Click cells to compare fundamentals
About Lipella Pharmaceuticals Financial Statements
Lipella Pharmaceuticals investors utilize fundamental indicators, such as Total Assets, to predict how Lipella Stock might perform in the future. Analyzing these trends over time helps investors make informed market timing decisions. For further insights, please visit our fundamental analysis page.
| Last Reported | Projected for Next Year | ||
| Total Assets | 3.6 M | 2.8 M |
Pair Trading with Lipella Pharmaceuticals
One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Lipella Pharmaceuticals position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Lipella Pharmaceuticals will appreciate offsetting losses from the drop in the long position's value.Moving together with Lipella Stock
| 0.67 | JNJ | Johnson Johnson Sell-off Trend | PairCorr |
| 0.68 | MRK | Merck Company Fiscal Year End 6th of February 2025 | PairCorr |
Moving against Lipella Stock
| 0.64 | BMY | Bristol Myers Squibb Sell-off Trend | PairCorr |
| 0.6 | NAMS | NewAmsterdam Pharma | PairCorr |
| 0.34 | PMVP | Pmv Pharmaceuticals | PairCorr |
| 0.33 | PHVS | Pharvaris BV | PairCorr |
The ability to find closely correlated positions to Lipella Pharmaceuticals could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Lipella Pharmaceuticals when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Lipella Pharmaceuticals - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Lipella Pharmaceuticals Common to buy it.
The correlation of Lipella Pharmaceuticals is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Lipella Pharmaceuticals moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Lipella Pharmaceuticals moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Lipella Pharmaceuticals can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.Check out the analysis of Lipella Pharmaceuticals Correlation against competitors. You can also try the Money Flow Index module to determine momentum by analyzing Money Flow Index and other technical indicators.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Lipella Pharmaceuticals. If investors know Lipella will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Lipella Pharmaceuticals listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (4.88) | Revenue Per Share 0.592 | Quarterly Revenue Growth 0.279 | Return On Assets (0.94) | Return On Equity (1.72) |
The market value of Lipella Pharmaceuticals is measured differently than its book value, which is the value of Lipella that is recorded on the company's balance sheet. Investors also form their own opinion of Lipella Pharmaceuticals' value that differs from its market value or its book value, called intrinsic value, which is Lipella Pharmaceuticals' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Lipella Pharmaceuticals' market value can be influenced by many factors that don't directly affect Lipella Pharmaceuticals' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Lipella Pharmaceuticals' value and its price as these two are different measures arrived at by different means. Investors typically determine if Lipella Pharmaceuticals is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Lipella Pharmaceuticals' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.